SERIOUS INFUSION REACTIONS, CAPILLARY LEAK SYNDROME AND LOSS OF VISUAL ACUITY
See full prescribing information for complete boxed warning.
- TRADE NAME: Ontak (Ligand)
- INDICATIONS: Cutaneous T-cell lymphoma
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
- HALF-LIFE: 70–80 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
BCG Vaccine, Belimumab, Denosumab, Leflunomide, Natalizumab, Pimecrolimus, Roflumilast, Sipuleucel-T, Tacrolimus, Trastuzumab, Vaccines
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
